These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 23402197)

  • 1. [Possibilities of triple antiviral therapy in chronic hepatitis C].
    Golovanova EV
    Eksp Klin Gastroenterol; 2012; (6):86-95. PubMed ID: 23402197
    [No Abstract]   [Full Text] [Related]  

  • 2. Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders.
    Brillanti S; Foli M; Di Tomaso M; Gramantieri L; Masci C; Bolondi L
    Ital J Gastroenterol Hepatol; 1999 Mar; 31(2):130-4. PubMed ID: 10363198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [An update on the management of chronic hepatitis C].
    Bihl F; Pache I; Hess J; Moradpour D
    Rev Med Suisse; 2010 Jan; 6(233):174, 176-9. PubMed ID: 20214188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenomic perspectives of chronic hepatitis C virus (HCV) infection.
    Tang J; Kaslow RA
    Pharmacogenomics J; 2004; 4(3):171-4. PubMed ID: 15069460
    [No Abstract]   [Full Text] [Related]  

  • 5. [Predicting factors in the efficacy of interferon treatment in chronic hepatitis C].
    Rodríguez Agulló JL
    An Med Interna; 2001 Jul; 18(7):349-50. PubMed ID: 11534417
    [No Abstract]   [Full Text] [Related]  

  • 6. Evaluation of microarray analysis for predicting treatment responsiveness in patients with chronic hepatitis C viral infection.
    Kim IJ; Kang HC; Park JG
    Gastroenterology; 2005 Nov; 129(5):1803; author reply 1803-4. PubMed ID: 16285984
    [No Abstract]   [Full Text] [Related]  

  • 7. Protease inhibitors in hepatitis C: from chronic disease to cure.
    Iqbal M; McCormick PA
    Ir Med J; 2011 Sep; 104(8):230-1. PubMed ID: 22125874
    [No Abstract]   [Full Text] [Related]  

  • 8. Hormones: a potential explanation for differences in response rates to therapy for chronic hepatitis C infection.
    Forde KA; Reddy KR
    Gastroenterology; 2011 Mar; 140(3):776-9. PubMed ID: 21262187
    [No Abstract]   [Full Text] [Related]  

  • 9. Haplotype-tagging RANTES gene variants influence response to antiviral therapy in chronic hepatitis C.
    Wasmuth HE; Werth A; Mueller T; Berg T; Dietrich CG; Geier A; Gartung C; Lorenzen J; Matern S; Lammert F
    Hepatology; 2004 Aug; 40(2):327-34. PubMed ID: 15368437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hepatitis C in 2007...progress and challenges].
    Marcellin P
    Gastroenterol Clin Biol; 2007; 31(8-9 Pt 3):4S3-6. PubMed ID: 17965628
    [No Abstract]   [Full Text] [Related]  

  • 11. Liver steatosis and antiviral therapy in chronic hepatitis C.
    Testino G; Sumberaz A
    Liver Int; 2007 Mar; 27(2):287. PubMed ID: 17311627
    [No Abstract]   [Full Text] [Related]  

  • 12. Has genetics eradicated the good old predictors of hepatitis C treatment response?
    Pawlotsky JM
    Clin Res Hepatol Gastroenterol; 2011 Mar; 35(3):157-8. PubMed ID: 21492738
    [No Abstract]   [Full Text] [Related]  

  • 13. [Chronic hepatitis C and B. What can be accomplished with antiviral therapy].
    MMW Fortschr Med; 2007 Feb; 149(7):14. PubMed ID: 17615650
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of tauroursodeoxycholic acid on ALT, GGT and viral load in patients with hepatitis C virus-related chronic hepatitis with reference to the genotype.
    Belloni G; Ferrari L; Balduzzi C; Barbieri F; Insolia R; Klersy C
    Ital J Gastroenterol Hepatol; 1999; 31(5):427. PubMed ID: 10470605
    [No Abstract]   [Full Text] [Related]  

  • 15. Gamma-glutamyltransferase activity and insulin resistance in chronic hepatitis C.
    Gentilcore E; Bugianesi E
    Dig Liver Dis; 2009 Aug; 41(8):553-4. PubMed ID: 19481509
    [No Abstract]   [Full Text] [Related]  

  • 16. [Combined antiviral treatment of a patient with chronic mixed hepatitis (HBV + HCV)].
    Fedorchenko SV; Martynovich TL
    Ter Arkh; 2006; 78(11):76-7. PubMed ID: 17195533
    [No Abstract]   [Full Text] [Related]  

  • 17. Management of treatment with direct-acting antiviral (DAA) in clinical practice.
    Fontanges T
    Clin Res Hepatol Gastroenterol; 2011 Dec; 35 Suppl 2():S64-8. PubMed ID: 22248697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Injecting drug users with chronic hepatitis C: should they be offered antiviral therapy?
    Foster GR
    Addiction; 2008 Sep; 103(9):1412-3. PubMed ID: 18783497
    [No Abstract]   [Full Text] [Related]  

  • 19. [Telaprevir: new possibilities for antiviral treatment in patients with chronic hepatitis C].
    Nikitin IG; Gogova LM; Baikova IE; Kislyakov VA; Volynkina VM
    Ter Arkh; 2012; 84(11):75-80. PubMed ID: 23252254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C.
    Brillanti S; Levantesi F; Masi L; Foli M; Bolondi L
    Hepatology; 2000 Sep; 32(3):630-4. PubMed ID: 10960460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.